Literature DB >> 6208720

Thalidomide treatment of prurigo nodularis.

R K Winkelmann, S M Connolly, J A Doyle, A Padilha-Goncalves.   

Abstract

Four patients with classic recalcitrant prurigo nodularis had symptomatic and physical responses to thalidomide with remissions. Three of the four patients had increased IgE levels that decreased during therapy. In two patients, short-term treatment (2 to 3 months) was not sufficient to produce remission, but retreatment was effective. Two patients had long-term remission with more than 6 months of treatment. No significant side effects occurred.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6208720

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  4 in total

Review 1.  Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations.

Authors:  V Günzler
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

2.  Effects of oral thalidomide on rat liver and skin microsomal P450 isozyme activities and on urinary porphyrin excretion: interaction with oral hexachlorobenzene.

Authors:  D Tsambaos; K Bolsen; S Georgiou; A Monastirli; G Goerz
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

3.  Thalidomide in dermatology: revisited.

Authors:  Iffat Hassan; Konchok Dorjay; Parvaiz Anwar
Journal:  Indian J Dermatol       Date:  2015 Mar-Apr       Impact factor: 1.494

Review 4.  A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis.

Authors:  Victoria M Lim; Eric L Maranda; Vivek Patel; Brian J Simmons; Joaquin J Jimenez
Journal:  Dermatol Ther (Heidelb)       Date:  2016-06-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.